Startseite>>Signaling Pathways>> GPCR/G protein>> Leukotriene Receptor>>ONO4057 (ONO-LB457)

ONO4057 (ONO-LB457) (Synonyms: ONO-LB457)

Katalog-Nr.GC32011

ONO4057 (ONO-LB457) ist ein Leukotrien-B4-Rezeptor-Antagonist mit einem IC50-Wert von 0,&7#177;0,3 ⋼M.

Products are for research use only. Not for human use. We do not sell to patients.

ONO4057 (ONO-LB457) Chemische Struktur

Cas No.: 134578-96-4

Größe Preis Lagerbestand Menge
1mg
1.471,00 $
Auf Lager
5mg
3.677,00 $
Auf Lager
10mg
6.251,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

ONO4057 is a Leukotriene B4 receptor antagonist, with an IC50 of 0.7±0.3 μM.

Mean animal survivals of the ONO4057-treated animals significantly prolong to 21.0±4.4 days compare with 12.0±0.6 days in control group. Histological findings from grafts taken on day 7 show that severe focal cellular infiltration is observed in both groups, but the degree of hepatocyte necrosis in ONO4057-treated anmimals is milder than that in control group[2].

[1]. Kishikawa K, et al. ONO-4057, a novel, orally active leukotriene B4 antagonist: effects on LTB4-induced neutrophil functions. Prostaglandins. 1992 Oct;44(4):261-75. [2]. Tanaka M, et al. Effect of leukotriene B(4) receptor antagonist (ONO4057) on hepatic allografting in rats. Transplant Proc. 2000 Nov;32(7):2340.

Bewertungen

Review for ONO4057 (ONO-LB457)

Average Rating: 5 ★★★★★ (Based on Reviews and 25 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ONO4057 (ONO-LB457)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.